Celiac Disease Genomic Environmental Microbiome and Metabolomic Study

Launched by MASSACHUSETTS GENERAL HOSPITAL · Feb 10, 2014

Keywords

ClinConnect Summary

The Celiac Disease Genomic Environmental Microbiome and Metabolomic Study (CDGEMM) is a research trial aimed at understanding what causes celiac disease (CD). Celiac disease is a serious condition triggered by eating gluten, a protein found in foods like wheat, rye, and barley. This study will look at various factors—like genetics, diet, and the gut bacteria that live in our intestines—to see how they might increase the risk of developing CD. By identifying these risk factors, the researchers hope to improve ways to prevent or detect the disease, especially in children who may be more likely to develop it.

To participate in this study, you must be a newborn or infant under 6 months old who has not started eating solid foods yet, or a first-degree relative (like a parent or sibling) of someone with confirmed celiac disease. Unfortunately, infants older than 6 months or those whose guardians cannot provide consent are not eligible. If you join the study, you can expect to contribute to important research that may help future generations by providing insights into celiac disease and how to manage it better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Newborns and infants less than 6 months of age who have not been introduced to solid foods (exclusive breast milk or formula diet)
• • First-degree relatives of patients affected with biopsy-proven CD
• Exclusion Criteria:
• • Infants older than 6 months of age
• • Inability or unwillingness of legal guardian/representative to give written informed consent